Pfizer Depreciation Amortization and Accretion vs Net Cash Flow or Change in Cash and Cash Equivalents Analysis

PFE
 Stock
  

USD 49.86  0.11  0.22%   

Pfizer financial indicator trend analysis is much more than just breaking down Pfizer Inc prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pfizer Inc is a good investment. Please check the relationship between Pfizer Depreciation Amortization and Accretion and its Net Cash Flow or Change in Cash and Cash Equivalents accounts. Please check Your Equity Center.

Depreciation Amortization and Accretion vs Net Cash Flow or Change in Cash and Cash Equivalents

Depreciation Amortization and Accretion vs Net Cash Flow or Change in Cash and Cash Equivalents Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pfizer Inc Depreciation Amortization and Accretion account and Net Cash Flow or Change in Cash and Cash Equivalents. At this time, the significance of the direction appears to have very week relationship.
The correlation between Pfizer's Depreciation Amortization and Accretion and Net Cash Flow or Change in Cash and Cash Equivalents is 0.28. Overlapping area represents the amount of variation of Depreciation Amortization and Accretion that can explain the historical movement of Net Cash Flow or Change in Cash and Cash Equivalents in the same time period over historical financial statements of Pfizer Inc, assuming nothing else is changed. The correlation between historical values of Pfizer's Depreciation Amortization and Accretion and Net Cash Flow or Change in Cash and Cash Equivalents is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Depreciation Amortization and Accretion of Pfizer Inc are associated (or correlated) with its Net Cash Flow or Change in Cash and Cash Equivalents. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Cash Flow or Change in Cash and Cash Equivalents has no effect on the direction of Depreciation Amortization and Accretion i.e., Pfizer's Depreciation Amortization and Accretion and Net Cash Flow or Change in Cash and Cash Equivalents go up and down completely randomly.

Correlation Coefficient

0.28
Relationship DirectionPositive 
Relationship StrengthVery Weak

Depreciation Amortization and Accretion

A component of operating cash flow representing the aggregate net amount of depreciation; amortization; and accretion recognized during an accounting period. As a non-cash item; the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.

Net Cash Flow or Change in Cash and Cash Equivalents

Principal component of the cash flow statement representing the amount of increase (decrease) in cash and cash equivalents. Includes Net Cash Flow from Operations; investing Net Cash Flow from Investing and financing Net Cash Flow from Financing for continuing and discontinued operations; and the effect of exchange rate changes on cash [NCFX].
Most indicators from Pfizer fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pfizer Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Please check Your Equity Center.Pfizer Issuance Repayment of Debt Securities is projected to based on the last few years of reporting. The past year's Issuance Repayment of Debt Securities was at 7.89 Billion. The current year Net Cash Flow Investment Acquisitions and Disposals is expected to grow to about 11.5 B, whereas Net Cash Flow Business Acquisitions and Disposals is forecasted to decline to (13.5 B).
 2019 2021 2022 (projected)
Consolidated Income16.3 B18.75 B17.02 B
Direct Expenses10.22 B30.82 B33.25 B

Pfizer fundamental ratios Correlations

0.360.660.24-0.090.48-0.280.810.580.490.170.340.61-0.59-0.730.130.240.76-0.350.650.410.170.21-0.46
0.360.060.90.730.310.330.16-0.20.470.910.170.360.190.140.030.50.130.33-0.070.610.820.80.25
0.660.060.11-0.050.04-0.160.720.660.06-0.040.180.13-0.8-0.76-0.20.280.83-0.540.78-0.1-0.31-0.23-0.57
0.240.90.110.730.20.320.18-0.070.240.880.140.220.150.09-0.030.740.210.280.030.440.60.590.29
-0.090.73-0.050.73-0.320.4-0.1-0.32-0.020.85-0.36-0.080.440.44-0.030.25-0.080.12-0.260.160.430.430.21
0.480.310.040.2-0.32-0.20.30.010.780.110.840.79-0.14-0.170.110.240.080.520.250.780.560.40.32
-0.280.33-0.160.320.4-0.2-0.41-0.31-0.330.32-0.21-0.390.290.260.080.17-0.210.26-0.66-0.150.210.170.27
0.810.160.720.18-0.10.3-0.410.870.340.080.090.43-0.5-0.830.360.250.76-0.540.740.11-0.15-0.15-0.59
0.58-0.20.66-0.07-0.320.01-0.310.87-0.1-0.24-0.130.07-0.56-0.920.370.190.72-0.730.64-0.31-0.55-0.5-0.69
0.490.470.060.24-0.020.78-0.330.34-0.10.320.620.86-0.05-0.030.020.020.020.350.290.870.70.560.1
0.170.91-0.040.880.850.110.320.08-0.240.32-0.030.220.380.30.080.34-0.030.22-0.160.460.690.650.21
0.340.170.180.14-0.360.84-0.210.09-0.130.62-0.030.63-0.41-0.12-0.430.310.080.550.390.680.440.360.38
0.610.360.130.22-0.080.79-0.390.430.070.860.220.63-0.15-0.160.030.120.180.290.430.880.530.330.18
-0.590.19-0.80.150.44-0.140.29-0.5-0.56-0.050.38-0.41-0.150.790.46-0.24-0.680.42-0.80.050.320.170.47
-0.730.14-0.760.090.44-0.170.26-0.83-0.92-0.030.3-0.12-0.160.79-0.16-0.24-0.780.63-0.710.160.40.30.67
0.130.03-0.2-0.03-0.030.110.080.360.370.020.08-0.430.030.46-0.16-0.170.02-0.2-0.3-0.12-0.07-0.17-0.2
0.240.50.280.740.250.240.170.250.190.020.340.310.12-0.24-0.24-0.170.460.250.290.230.220.240.29
0.760.130.830.21-0.080.08-0.210.760.720.02-0.030.080.18-0.68-0.780.020.46-0.550.69-0.06-0.27-0.18-0.53
-0.350.33-0.540.280.120.520.26-0.54-0.730.350.220.550.290.420.63-0.20.25-0.55-0.410.60.680.520.93
0.65-0.070.780.03-0.260.25-0.660.740.640.29-0.160.390.43-0.8-0.71-0.30.290.69-0.410.15-0.24-0.19-0.43
0.410.61-0.10.440.160.78-0.150.11-0.310.870.460.680.880.050.16-0.120.23-0.060.60.150.840.680.45
0.170.82-0.310.60.430.560.21-0.15-0.550.70.690.440.530.320.4-0.070.22-0.270.68-0.240.840.930.51
0.210.8-0.230.590.430.40.17-0.15-0.50.560.650.360.330.170.3-0.170.24-0.180.52-0.190.680.930.33
-0.460.25-0.570.290.210.320.27-0.59-0.690.10.210.380.180.470.67-0.20.29-0.530.93-0.430.450.510.33
Click cells to compare fundamentals

Pfizer Account Relationship Matchups

Pfizer fundamental ratios Accounts

201720182019202020212022 (projected)
Inventories7.58 B7.51 B8.28 B8.05 B9.06 B7.92 B
Receivables8.22 B8.03 B8.72 B7.93 B11.48 B11.8 B
Accounts Payable4.66 B4.67 B4.22 B4.31 B5.58 B4.7 B
Accumulated Other Comprehensive Income(11.04 B)(9.32 B)(11.28 B)(11.64 B)(10.48 B)(11.3 B)
Total Assets171.8 B159.42 B167.49 B154.23 B181.48 B196.04 B
Current Assets41.14 B49.93 B32.8 B35.07 B59.69 B60.12 B
Assets Non Current132.67 B130.66 B109.5 B134.69 B121.22 B117.09 B
Cash and Equivalents1.34 B1.14 B1.3 B1.78 B1.94 B2.71 B
Cash and Equivalents USD2.6 B1.34 B1.14 B1.3 B1.17 B1.21 B
Total Debt42.09 B43.49 B41.74 B52.15 B59.97 B55.81 B
Debt Current10.69 B9.95 B8.83 B16.2 B18.62 B20.09 B
Debt Non Current31.4 B33.54 B32.91 B35.95 B32.36 B31.27 B
Total Debt USD42.09 B43.49 B41.74 B52.15 B59.97 B55.81 B
Shareholders Equity71.31 B63.41 B63.14 B63.24 B77.2 B82.19 B
Shareholders Equity USD59.54 B71.31 B63.41 B63.14 B56.83 B60.95 B
Goodwill and Intangible Assets107.1 B104.69 B88.62 B94.02 B84.62 B84.29 B
Inventory6.78 B7.58 B7.51 B8.28 B7.45 B7.1 B
Investments22.37 B25.66 B20.46 B28.67 B25.8 B27.9 B
Investments Current15.26 B18.65 B17.69 B8.53 B7.67 B7.87 B
Investments Non Current7.12 B7.01 B2.77 B20.15 B18.13 B14.66 B
Total Liabilities100.49 B96.02 B104.34 B90.99 B104.28 B113.85 B
Current Liabilities30.43 B31.86 B37.3 B25.92 B42.67 B35.05 B
Liabilities Non Current80.66 B69.71 B63.81 B66.74 B60.06 B62.82 B
Trade and Non Trade Payables4.54 B4.66 B4.67 B4.22 B4.85 B4.82 B
Property Plant and Equipment Net13.32 B13.87 B13.38 B13.97 B12.57 B12.86 B
Trade and Non Trade Receivables8.22 B8.22 B8.03 B8.72 B7.85 B8.38 B
Accumulated Retained Earnings Deficit71.77 B85.29 B89.55 B97.67 B112.32 B98.16 B
Tax Assets4.85 B4.91 B5.3 B5.44 B4.9 B5.79 B
Tax Liabilities35.19 B23.07 B19.7 B18.68 B16.82 B20.51 B

Pfizer Investors Sentiment

The influence of Pfizer's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Pfizer. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Pfizer's public news can be used to forecast risks associated with investment in Pfizer. The trend in average sentiment can be used to explain how an investor holding Pfizer can time the market purely based on public headlines and social activities around Pfizer Inc. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Pfizer's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Pfizer's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Pfizer's news discussions. The higher the estimate score, the more favorable is the investor's outlook on Pfizer.

Pfizer Implied Volatility

    
  30.34  
Pfizer's implied volatility exposes the market's sentiment of Pfizer Inc stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Pfizer's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Pfizer stock will not fluctuate a lot when Pfizer's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Pfizer in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Pfizer's short interest history, or implied volatility extrapolated from Pfizer options trading.

Currently Active Assets on Macroaxis

Please check Your Equity Center. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for Pfizer Stock analysis

When running Pfizer Inc price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
0.77
Market Capitalization
278.3 B
Quarterly Revenue Growth YOY
0.47
Return On Assets
0.13
Return On Equity
0.37
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine Pfizer value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.